Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease

✍ Scribed by Dr. W. Poewe; G. Luef; B. Kleedorfer; M. Emre

• Publisher: John Wiley and Sons
• Year: 1990
• Tongue: English
• Weight: 255 KB
• Volume: 5
• Category: Article
• ISSN: 0885-3185
• DOI: 10.1002/mds.870050315

✦ Synopsis

Abstract

Six patients with fluctuating Parkinson's disease received single rising oral doses of the nonergot dopamine agonist CV 205‐502 in an open experimental study. Doses of 0.5 mg produced antiparkinsonian effects of comparable intensity but longer duration than 200 mg of L‐DOPA. CV 205‐502, which combines structural features common to both ergolines and apomorphine, thus revealed interesting antiparkinsonian properties, but nausea and vomiting were dose‐limiting side effects in all patients tested.